J&J Pharma Sales Force Reduced As Part Of Efficiencies Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm says it has implemented a "modest" sales force reduction.
You may also be interested in...
J&J To Launch Prezista For HIV Immediately Following FDA Approval
Darunavir - formerly known as TMC-114 - in combination with ritonavir is approved for treatment-experienced adults who do not respond to other antiretrovirals.
J&J’s Prezista Approved For Treatment-Resistant HIV
The protease inhibitor – formerly known as TMC-114 – is to be co-administered with a low dose of ritonavir.
J&J To Launch Prezista For HIV Immediately Following FDA Approval
Darunavir - formerly known as TMC-114 - in combination with ritonavir is approved for treatment-experienced adults who do not respond to other antiretrovirals.